Please login to the form below

Not currently logged in
Email:
Password:

mirabegron

This page shows the latest mirabegron news and features for those working in and with pharma, biotech and healthcare.

Urovant slips on phase 3 incontinence drug data

Urovant slips on phase 3 incontinence drug data

Vibegron was licensed from Merck &Co/MSD in 2017 and is billed as an improved version of Astellas’ Myrbetriq/Betmiga (mirabegron), which was the first beta3-adrenergic agonist to reach the

Latest news

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • Astellas: Ten years young Astellas: Ten years young

    In Europe we have been launching a product almost every single year,” notes Ken, pointing to products such as the overactive bladder (OAB) drug Betmiga (mirabegron) - the first of a new

  • Interview: Ken Jones, Astellas Pharma Europe Interview: Ken Jones, Astellas Pharma Europe

    Urology is a key strategic area for Astellas and we have a strong pipeline in this therapy area; we are currently getting prepared with Mirabegron, a drug to treat overactive bladder,

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Infographics